FibroGen Statistics
Total Valuation
FibroGen has a market cap or net worth of $23.24 million. The enterprise value is $80.85 million.
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroGen has 4.04 million shares outstanding. The number of shares has increased by 2.20% in one year.
| Current Share Class | 4.04M |
| Shares Outstanding | 4.04M |
| Shares Change (YoY) | +2.20% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 1.50% |
| Owned by Institutions (%) | 24.51% |
| Float | 3.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.31 |
| Forward PS | 0.14 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.02
| Current Ratio | 2.02 |
| Quick Ratio | 0.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.73% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -105.17% |
| Revenue Per Employee | $31,093 |
| Profits Per Employee | -$44,476 |
| Employee Count | 225 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 4.12 |
Taxes
| Income Tax | -274,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.67% in the last 52 weeks. The beta is 0.82, so FibroGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -77.67% |
| 50-Day Moving Average | 7.54 |
| 200-Day Moving Average | 9.68 |
| Relative Strength Index (RSI) | 32.81 |
| Average Volume (20 Days) | 49,207 |
Short Selling Information
The latest short interest is 3.71 million, so 91.84% of the outstanding shares have been sold short.
| Short Interest | 3.71M |
| Short Previous Month | 4.68M |
| Short % of Shares Out | 91.84% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.22 |
Income Statement
In the last 12 months, FibroGen had revenue of $7.00 million and -$10.01 million in losses. Loss per share was -$2.49.
| Revenue | 7.00M |
| Gross Profit | -55.85M |
| Operating Income | -96.57M |
| Pretax Income | -168.39M |
| Net Income | -10.01M |
| EBITDA | -94.38M |
| EBIT | -96.57M |
| Loss Per Share | -$2.49 |
Full Income StatementBalance Sheet
The company has $33.61 million in cash and $91.22 million in debt, giving a net cash position of -$57.61 million or -$14.25 per share.
| Cash & Cash Equivalents | 33.61M |
| Total Debt | 91.22M |
| Net Cash | -57.61M |
| Net Cash Per Share | -$14.25 |
| Equity (Book Value) | -174.93M |
| Book Value Per Share | -53.66 |
| Working Capital | 75.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$75.99 million and capital expenditures -$253,000, giving a free cash flow of -$76.25 million.
| Operating Cash Flow | -75.99M |
| Capital Expenditures | -253,000 |
| Free Cash Flow | -76.25M |
| FCF Per Share | -$18.86 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,380.42% |
| Pretax Margin | -1,730.87% |
| Profit Margin | -143.04% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.20% |
| Shareholder Yield | -2.20% |
| Earnings Yield | -43.06% |
| FCF Yield | -328.08% |
Analyst Forecast
The average price target for FibroGen is $250.00, which is 4,247.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $250.00 |
| Price Target Difference | 4,247.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | -16.38% |
| EPS Growth Forecast (5Y) | -51.78% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 17, 2025. It was a reverse split with a ratio of 0.04:1.
| Last Split Date | Jun 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.04:1 |
Scores
FibroGen has an Altman Z-Score of -17.19 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.19 |
| Piotroski F-Score | 1 |